AB SCIENCE SA (AB.PA) Fundamental Analysis & Valuation

EPA:AB • FR0010557264

Current stock price

1.204 EUR
-0.01 (-0.82%)
Last:

This AB.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. AB.PA Profitability Analysis

1.1 Basic Checks

  • AB had negative earnings in the past year.
  • In the past year AB has reported a negative cash flow from operations.
  • AB had negative earnings in each of the past 5 years.
  • AB had negative operating cash flow in 4 of the past 5 years.
AB.PA Yearly Net Income VS EBIT VS OCF VS FCFAB.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • With a Return On Assets value of -40.25%, AB is not doing good in the industry: 80.77% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -40.25%
ROE N/A
ROIC N/A
ROA(3y)-45.97%
ROA(5y)-51.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AB.PA Yearly ROA, ROE, ROICAB.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

  • With an excellent Gross Margin value of 90.75%, AB belongs to the best of the industry, outperforming 94.23% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AB has grown nicely.
  • AB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.74%
GM growth 5Y5.64%
AB.PA Yearly Profit, Operating, Gross MarginsAB.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. AB.PA Health Analysis

2.1 Basic Checks

  • AB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AB has been increased compared to 1 year ago.
  • Compared to 5 years ago, AB has more shares outstanding
  • Compared to 1 year ago, AB has a worse debt to assets ratio.
AB.PA Yearly Shares OutstandingAB.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
AB.PA Yearly Total Debt VS Total AssetsAB.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • AB has an Altman-Z score of -19.98. This is a bad value and indicates that AB is not financially healthy and even has some risk of bankruptcy.
  • AB has a worse Altman-Z score (-19.98) than 82.69% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.98
ROIC/WACCN/A
WACC8.12%
AB.PA Yearly LT Debt VS Equity VS FCFAB.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

2.3 Liquidity

  • AB has a Current Ratio of 0.67. This is a bad value and indicates that AB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.67, AB is not doing good in the industry: 88.46% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.67 indicates that AB may have some problems paying its short term obligations.
  • The Quick ratio of AB (0.67) is worse than 80.77% of its industry peers.
Industry RankSector Rank
Current Ratio 0.67
Quick Ratio 0.67
AB.PA Yearly Current Assets VS Current LiabilitesAB.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AB.PA Growth Analysis

3.1 Past

  • AB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.25%.
  • The Revenue has decreased by -5.08% in the past year.
  • Measured over the past years, AB shows a decrease in Revenue. The Revenue has been decreasing by -7.36% on average per year.
EPS 1Y (TTM)-23.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.33%
Revenue 1Y (TTM)-5.08%
Revenue growth 3Y-12.62%
Revenue growth 5Y-7.36%
Sales Q2Q%-8.04%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.95% on average over the next years. This is quite good.
  • AB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 70.12% yearly.
EPS Next Y65.85%
EPS Next 2Y29.73%
EPS Next 3Y18.95%
EPS Next 5YN/A
Revenue Next Year-3%
Revenue Next 2Y0%
Revenue Next 3Y5.73%
Revenue Next 5Y70.12%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AB.PA Yearly Revenue VS EstimatesAB.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 2031 2032 2033 100M 200M 300M
AB.PA Yearly EPS VS EstimatesAB.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8

More info and screens

Find the best growth stocksShow best growing peers

0

4. AB.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AB. In the last year negative earnings were reported.
  • Also next year AB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AB.PA Price Earnings VS Forward Price EarningsAB.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AB.PA Per share dataAB.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • AB's earnings are expected to grow with 18.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.73%
EPS Next 3Y18.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AB.PA Dividend Analysis

5.1 Amount

  • AB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AB.PA Fundamentals: All Metrics, Ratios and Statistics

AB SCIENCE SA

EPA:AB (3/20/2026, 7:00:00 PM)

1.204

-0.01 (-0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-30
Earnings (Next)05-11
Inst Owners0%
Inst Owner ChangeN/A
Ins Owners30.8%
Ins Owner ChangeN/A
Market Cap79.68M
Revenue(TTM)1.03M
Net Income(TTM)-8.54M
Analysts84.44
Price Target3.79 (214.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.06%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-7.69%
EPS NY rev (3m)-7.69%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 77.59
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.02
BVpS-0.41
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.25%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.75%
FCFM N/A
ROA(3y)-45.97%
ROA(5y)-51.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.74%
GM growth 5Y5.64%
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.43%
Cap/Sales 19.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.67
Quick Ratio 0.67
Altman-Z -19.98
F-Score3
WACC8.12%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)39.08%
Cap/Sales(5y)35.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.33%
EPS Next Y65.85%
EPS Next 2Y29.73%
EPS Next 3Y18.95%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.08%
Revenue growth 3Y-12.62%
Revenue growth 5Y-7.36%
Sales Q2Q%-8.04%
Revenue Next Year-3%
Revenue Next 2Y0%
Revenue Next 3Y5.73%
Revenue Next 5Y70.12%
EBIT growth 1Y35.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.66%
EBIT Next 3Y20.03%
EBIT Next 5YN/A
FCF growth 1Y61.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.21%
OCF growth 3YN/A
OCF growth 5YN/A

AB SCIENCE SA / AB.PA Fundamental Analysis FAQ

What is the fundamental rating for AB stock?

ChartMill assigns a fundamental rating of 1 / 10 to AB.PA.


What is the valuation status for AB stock?

ChartMill assigns a valuation rating of 0 / 10 to AB SCIENCE SA (AB.PA). This can be considered as Overvalued.


What is the profitability of AB stock?

AB SCIENCE SA (AB.PA) has a profitability rating of 1 / 10.


How financially healthy is AB SCIENCE SA?

The financial health rating of AB SCIENCE SA (AB.PA) is 0 / 10.


What is the expected EPS growth for AB SCIENCE SA (AB.PA) stock?

The Earnings per Share (EPS) of AB SCIENCE SA (AB.PA) is expected to grow by 65.85% in the next year.